An Open Label, Multi-center, Phase I Clinical Study to Evaluate the Safety, Effectiveness and Pharmacokinetic Characteristics of SIM1803-1A in Patients With Locally Advanced/Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Mutations.

PHASE1UnknownINTERVENTIONAL

Enrollment

243

Participants

Timeline

Start Date

December 21, 2020

Primary Completion Date

September 30, 2022

Study Completion Date

January 30, 2024

Conditions

Advanced or Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion

Interventions

DRUG

SIM1803-1A

SIM1803-1A will be administered orally as tablets at a given dose once daily in continuing 21-days cycles.

Trial Locations (1)

RECRUITING

Shanghai Chest Hospital, Shanghai